Marine Diterpenoids as Potential Anti-Inflammatory Agents

Yisett González1, Daniel Torres-Mendoza2, Gillian E Jones3

  • 1Centro de Biología Celular y Molecular de Enfermedades, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Ciudad de Panamá, Panama ; Department of Biotechnology, Acharya Nagarjuna University, Guntur 522510, India.

Mediators of Inflammation
|November 6, 2015
PubMed
Summary

Marine diterpenoids, natural compounds from organisms like corals, show significant anti-inflammatory properties. These molecules offer potential for new treatments by inhibiting key inflammatory pathways.

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
669
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
627
Marine Microbial Ecology01:30

Marine Microbial Ecology

Marine microbial ecosystems are shaped by distinct physicochemical limits, including high salinity, low nutrient availability, and fluctuating oxygen levels. These conditions favor smaller microbial cell sizes, which maximize their surface-to-volume ratio for efficient nutrient uptake.Microbial activity and community composition are closely linked to biogeochemical cycles, particularly in dynamic environments like estuaries, where halotolerant microbes thrive in response to variable salinity...
39
Microbial Bioremediation of Hydrocarbons01:26

Microbial Bioremediation of Hydrocarbons

Bioremediation is an environmentally sustainable process that employs living organisms—primarily microorganisms—to degrade or neutralize pollutants from contaminated environments. In oil spills and hydrocarbon pollution, bioremediation involves the use of hydrocarbon-degrading bacteria to transform toxic compounds into less harmful substances. This approach leverages natural microbial metabolic processes and is considered both cost-effective and ecologically favorable compared to...
52
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
749